Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
EGFL7 encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. Additionally we are shipping EGFL7 Kits (14) and EGFL7 Proteins (8) and many more products for this protein.
Showing 10 out of 63 products:
Human Polyclonal EGFL7 Primary Antibody for IF (cc), IF (p) - ABIN733988
Huang, Yuan, Wan, Liu, Chen, Zhan, Li: VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network. in International journal of clinical and experimental pathology 2014
Human Monoclonal EGFL7 Primary Antibody for ELISA - ABIN565551
Badiwala, Tumiati, Joseph, Sheshgiri, Ross, Delgado, Rao: Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. in Circulation 2010
Human Monoclonal EGFL7 Primary Antibody for ELISA, WB - ABIN565550
Fish, Santoro, Morton, Yu, Yeh, Wythe, Ivey, Bruneau, Stainier, Srivastava: miR-126 regulates angiogenic signaling and vascular integrity. in Developmental cell 2008
Human Polyclonal EGFL7 Primary Antibody for ELISA, WB - ABIN4365051
Delfortrie, Pinte, Mattot, Samson, Villain, Caetano, Lauridant-Philippin, Baranzelli, Bonneterre, Trottein, Faveeuw, Soncin: Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. in Cancer research 2011
we demonstrate for the first time the mechanisms by which lumens are generated within the major vessels in Xenopus and implicate EGFL7 in modulating cell shape and cell-cell junctions to drive proper lumen morphogenesis.
CASZ1 (show CASZ1 Antibodies)/Egfl7/RhoA (show RHOA Antibodies) pathway is necessary for promoting endothelial cell behaviors associated with proper vascular assembly.
These data suggest that Egfl7 provides endothelial cells (EC) with a cue for their extension into the vascular area and in establishing EC cell polarity.
EGFL7 provides a proper microenvironment for endothelial cell migration, thereby enabling accurate patterning.
EGFL7 is required for VEGF (show VEGFA Antibodies) upregulation of the Akt (show AKT1 Antibodies)/Erk (1 (show MAPK3 Antibodies)/2) pathway during angiogenesis.
EGFL7 enhances EGFR (show EGFR Antibodies)-AKT (show AKT1 Antibodies) signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.
Egfl7 could be a HIF-1alpha (show HIF1A Antibodies) responsive gene regulated by oxygen tension.
Using the BPH/5 model of pre-eclampsia (PE), we show that the downregulation of Egfl7 in compromised placentas occurs pr (show NOTCH1 Antibodies)ior to the onset of characteristic maternal signs of PE.
egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries.
EGFL7 is expressed in the bone microenvironment and has a role in promoting endothelial cell migration and tube-like structure formation through integrin-mediated pathways.
Expression of Egfl7 in breast and lung carcinoma cells accelerates tumor growth and metastasis in immunocompetent mice but not in immunodeficient mice.
Overexpression of endothelial Egfl7 is associated with impaired angiogenesis and altered Notch (show NOTCH1 Antibodies) signaling
the expression of the VE-statin/egfl7 gene in endothelial cells and the specific importance of ETS (show ETS1 Antibodies) and GATA (show QRSL1 Antibodies) factors
EGFL7 protein is localized to the endoplasmic reticulum and Golgi apparatus, suggesting that the protein is targeted for secretion
The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF (show VEGFA Antibodies), suggests a possible important role of this angiogenic factor (show VEGFA Antibodies) in a later oncogenic and infiltrative/metastatic phase.
EGFR (show EGFR Antibodies) mutational analysis is useful in the diagnosis of non-small-cell-lung cancer.
The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor (show EGF Antibodies)-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer.
EGFL7, OPN (show SPP1 Antibodies), and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma
High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer.
Loss of EGFL7 expression is associated with Malignant Pleural Mesothelioma.
Data suggest that, in trophoblast cells, EGFL7 regulates cell migration and invasion/placentation by activating multiple signaling pathways via MAPK (show MAPK1 Antibodies), PI3K (show PIK3CA Antibodies) (phosphatidylinositol 3-kinase), and NOTCH1 (show NOTCH1 Antibodies) (translocation-associated notch (show NOTCH1 Antibodies) protein 1).
EGFL7 may predict response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer
Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling.
This gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants.
EGF-like-domain, multiple 7
, epidermal growth factor-like protein 7
, EGF-like protein 7
, NEU1 protein
, NOTCH4-like protein
, multiple EGF-like domains protein 7
, multiple epidermal growth factor-like domains protein 7
, vascular endothelial statin
, vascular endothelial-statin
, EGF-like domain 7
, EGF-like domain-containing protein 7
, Estrogen-regulated protein CBL20 20.4kD
, Estrogen-regulated protein CBL20, 20.4kD
, multiple EGF-like domain protein 7
, multiple epidermal growth factor-like domain protein 7